FGFR3 S249C
|
Urothelial Cancer
|
FGFR3 S249C
|
Urothelial Cancer
|
infigratinib Sensitive: C3 – Early Trials
|
infigratinib Sensitive: C3 – Early Trials
|
FGFR3 S249C
|
Urothelial Cancer
|
FGFR3 S249C
|
Urothelial Cancer
|
erdafitinib Sensitive: C3 – Early Trials
|
erdafitinib Sensitive: C3 – Early Trials
|
FGFR3 S249C
|
Urothelial Cancer
|
FGFR3 S249C
|
Urothelial Cancer
|
FGFR2 inhibitor Resistant: C3 – Early Trials
|
FGFR2 inhibitor Resistant: C3 – Early Trials
|
FGFR3 S249C
|
Urothelial Cancer
|
FGFR3 S249C
|
Urothelial Cancer
|
FGFR3 inhibitor Resistant: C3 – Early Trials
|
FGFR3 inhibitor Resistant: C3 – Early Trials
|
FGFR3 S249C
|
Urothelial Cancer
|
FGFR3 S249C
|
Urothelial Cancer
|
pazopanib Sensitive: C4 – Case Studies
|
pazopanib Sensitive: C4 – Case Studies
|
FGFR3 S249C
|
LUAD
|
FGFR3 S249C
|
LUAD
|
infigratinib Sensitive: D – Preclinical
|
infigratinib Sensitive: D – Preclinical
|
FGFR3 S249C
|
Urothelial Cancer
|
FGFR3 S249C
|
Urothelial Cancer
|
AZ8010 Sensitive: D – Preclinical
|
AZ8010 Sensitive: D – Preclinical
|
FGFR3 S249C
|
Urothelial Cancer
|
FGFR3 S249C
|
Urothelial Cancer
|
PD 0173074 Sensitive: D – Preclinical
|
PD 0173074 Sensitive: D – Preclinical
|
FGFR3 S249C
|
Urothelial Cancer
|
FGFR3 S249C
|
Urothelial Cancer
|
ABSK091 Sensitive: D – Preclinical
|
ABSK091 Sensitive: D – Preclinical
|
FGFR3 S249C
|
Bladder Cancer
|
FGFR3 S249C
|
Bladder Cancer
|
ponatinib Sensitive: D – Preclinical
|
ponatinib Sensitive: D – Preclinical
|